2. Fisher BL, Schauer P. Medical and surgical options in the treatment of severe obesity. Am J Surg. 2002;184:S9–S16.
3. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use and diversion of prescription stimulant medication. J Psychoactive Drugs. 2006;38:43–56.
4. Arnsten AF. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology. 2006;31:2376–2383.
5. Gyllenhaal C, Merritt SL, Peterson SD, et al. Efficacy and safety of herbal stimulants and sedatives in sleep disorders. Sleep Med Rev. 2000;4:229–251.
6. Sofuoglu M, Dudish-Poulsen S, Nelson D, et al. Sex and menstrual cycle differences in the subjective effects from smoked cocaine
in humans. Exp Clin Psychopharmacol. 1999;7:274–283.
7. Evans SM, Foltin RW. Exogenous progesterone attenuates the subjective effects of smoked cocaine
in women, but not in men. Neuropsychopharmacology. 2006;31:659–674.
8. White TL, Justice AJ, de Wit H. Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav. 2002;73:729–741.
9. Roth ME, Cosgrove KP, Carroll ME. Sex differences in the vulnerability to drug abuse: a review of preclinical studies. Neurosci Biobehav Rev. 2004;28:533–546.
10. Brecht M-L, O’Brien A, Von Mayrhauser C, et al. Methamphetamine
use behaviors and gender differences. Addict Behav. 2004;29:89–106.
11. Joe KA. Ice is strong enough for a man but made for a woman. Crime Law Social Change. 1994;22:269–289.
12. Miller J, Carbone-Lopez K, Gunderman MVPresser L, Sandberg S. Gendered narratives of self, addiction, and recovery among women methamphetamine
users. Narrative Criminology: Understanding Stories of Crime. 2015:69–95.
13. Lynch W, Potenza MN, Cosgrove KP, et alBrady KT, Back SE, Greenfield SF. Sex differences in vulnerability to stimulant abuse. Women and Addiction: A Comprehensive Handbook. New York, NY: Guilford; 2009:409–418.
14. Tuchman E. Women and addiction: the importance of gender issues in substance abuse research. J Addict Dis. 2010;29:127–138–117–.
15. Wright TE, Schuetter R, Tellei J, et al. Methamphetamines and pregnancy
outcomes. J Addict Med. 2015;9:111–117.
16. Oei JL, Abdel-Latif ME, Clark R, et al. Short-term outcomes of mothers and infants exposed to antenatal amphetamines. Arch Dis Child FetalNeonatal Ed. 2009;95:F36–F41.
17. Boeri MW, Tyndall BD, Woodall DR. Suburban poverty: barriers to services and injury prevention among marginalized women who use methamphetamine
. West J Emerg Med. 2011;12:284–292.
18. Wermuth L. Poverty and methamphetamine
abuse: a study of AIDS risk behaviors among rural Northern California Women. J Poverty. 1999;3:25–45.
19. Kissin WB, Svikis DS, Morgan GD, et al. Characterizing pregnant drug-dependent women in treatment and their children. J Subst Abuse Treat. 2001;21:27–34.
20. Martin SL, English KT, Clark KA, et al. Violence and substance use among North Carolina pregnant women. Am J Public Health. 1996;86:991–998.
21. Hedin LW, Janson PO. Domestic violence during pregnancy
: the prevalence of physical injuries, substance use, abortions and miscarriages. Acta Obstet Gynecol Scand. 2000;79:625–630.
22. Krans EE, Patrick SW. Opioid use disorder in pregnancy
: health policy and practice in the midst of an epidemic. Obstet Gynecol. 2016;128:4–10.
23. Terplan M. Why is there no moral panic surrounding methamphetamine
use in pregnancy
in the US? Adiktologie. 2008;8:300–301.
24. Terplan M, Smith EJ, Kozloski MJ, et al. Methamphetamine
use among pregnant women. Obstet Gynecol. 2009;113:1285–1291.
25. Gold MS, Washton AM, Dackis CA. Cocaine
abuse: neurochemistry, phenomenology, and treatment. Cocaine
use in America: epidemiologic and clinical perspectives. NIDA Res Monogr. 1985;61:130–150.
26. Pitts D, Marwah J. Autonomic actions of cocaine
. Can J Physiol Pharmacol. 1989;67:1168–1176.
27. Krishna RB, Levitz M, Dancis J. Transfer of cocaine
by the perfused human placenta: the effect of binding to serum proteins. Am J Obstet Gynecol. 1993;169:1418–1423.
28. Sheinkopf SJ, Lagasse LL, Lester BM, et al. Prenatal cocaine
exposure: cardiorespiratory function and resilience. Ann N Y Acad Sci. 2006;1094:354–358.
29. Chavkin W. Cocaine
—time to look at the evidence. JAMA. 2001;285:1626–1628.
31. Jarlenski M, Barry CL, Gollust S, et al. Polysubstance use among US women of reproductive age who use opioids for nonmedical reasons. Am J Public Health. 2017;107:1308–1310.
32. Day NL, Cottreau CM, Richardson GA. The epidemiology of alcohol, marijuana, and cocaine
use among women of childbearing age and pregnant women. Clin Obstet Gynecol. 1993;36:232–245.
33. Richardson GA, Day NL, Mcgauhey PJ. The impact of prenatal marijuana and cocaine
use on the infant and child. Clin Obstet Gynecol. 1993;36:302–318.
34. Cox S, Posner SF, Kourtis AP, et al. Hospitalizations with amphetamine abuse among pregnant women. Obstet Gynecol. 2008;111:341–347.
35. Lampley EC, Williams S, Myers SA. Cocaine
-associated rhabdomyolysis causing renal failure in pregnancy
. Obstet Gynecol. 1996;87:804–806.
36. Moen MD, Caliendo MJ, Marshall W, et al. Hepatic rupture in pregnancy
associated with cocaine
use. Obstet Gynecol. 1993;82(pt 2 suppl):687–689.
37. Mercado A, Johnson JG, Calver D, et al. Cocaine
, and postpartum intracerebral hemorrhage. Obstet Gynecol. 1989;73(pt 2):467–468.
38. Lange RA, Hillis LD. Cardiovascular complications of cocaine
use. N Engl J Med. 2001;345:351–358.
39. Towers CV, Pircon RA, Nageotte MP, et al. Cocaine
intoxication presenting as preeclampsia and eclampsia. Obstet Gynecol. 1993;81:545–547.
40. Slutsker L. Risks associated with cocaine
use during pregnancy
. Obstet Gynecol. 1992;79(pt 1):778–789.
41. Burkett G, Bandstra ES, Cohen J, et al. Cocaine
-related maternal death. Am J Obstet Gynecol. 1990;163:40–41.
42. Kuczkowski KM. The effects of drug abuse on pregnancy
. Curr Opin Obstet Gynecol. 2007;19:578–585.
43. Woods JR, Plessinger MA. Pregnancy
increases cardiovascular toxicity to cocaine
. Am J Obstet Gynecol. 1990;162:529–533.
44. Plessinger MA, Woods JR. Progesterone increases cardiovascular toxicity to cocaine
in nonpregnant ewes. Am J Obstet Gynecol. 1990;163:1659–1664.
45. Plessinger MA, Woods JR Jr. The cardiovascular effects of cocaine
use in pregnancy
. Reprod Toxicol. 1991;5:99–113.
46. Sharma A, Plessinger MA, Sherer DM, et al. Pregnancy
enhances cardiotoxicity of cocaine
: role of progesterone. Toxicol Appl Pharmacol. 1992;113:30–35.
47. Kuczkowski KM. Anesthetic implications of drug abuse in pregnancy
. J Clin Anesth. 2003;15:382–394.
48. Plessinger MA, Woods JJ. Maternal, placental, and fetal pathophysiology of cocaine
exposure during pregnancy
. Clin Obstet Gynecol. 1993;36:267–278.
49. Bauer CR, Langer JC, Shankaran S, et al. Acute neonatal effects of cocaine
exposure during pregnancy
. Arch Pediatr Adolesc Med. 2005;159:824–834.
50. Chavez G, Mulinare J, Cordero J. Maternal cocaine
use during early pregnancy
as a risk factor for congenital urogenital anomalies. Int J Gynecol Obstet. 1990;31:309.
51. Chavez G, Mulinare J, Cordero J. Maternal cocaine
use and the risk for genitourinary tract defects: an epidemiologic approach. Am J Human Genetics. 1988;43:A43.
52. Chávez GF, Mulinare J, Cordero JF. Maternal cocaine
use during early pregnancy
as a risk factor for congenital urogenital anomalies. JAMA. 1989;262:795–798.
53. Hoyme HE, Jones KL, Dixon SD, et al. Prenatal cocaine
exposure and fetal vascular disruption. Pediatrics. 1990;85:743–747.
54. Gouin K, Murphy K, Shah PS. Effects of cocaine
use during pregnancy
on low birthweight and preterm birth: systematic review and metaanalyses. Am J Obstet Gynecol. 2011;204:340. e1–e12.
55. Dombrowski MP, Wolfe HM, Welch RA, et al. Cocaine
abuse is associated with abruptio placentae and decreased birth weight, but not shorter labor. Obstet Gynecol. 1991;77:139–141.
56. Webbeh H, Matthews RP, McCalla S, et al. The effect of recent cocaine
use on the progress of labor. Am J Obstet Gynecol. 1995;172:1014–1018.
57. Ness RB, Grisso JA, Hirschinger N, et al. Cocaine
and tobacco use and the risk of spontaneous abortion. N Engl J Med. 1999;340:333–339.
58. Bingol N, Fuchs M, Diaz V, et al. Teratogenicity of cocaine
in humans. J Pediatr. 1987;110:93–96.
59. Acker D, Sachs BP, Tracey KJ, et al. Abruptio placentae associated with cocaine
use. Am J Obstet Gynecol. 1983;146:220–221.
60. Chasnoff IJ, Burns WJ, Schnoll SH, et al. Cocaine
use in pregnancy
. N Engl J Med. 1985;313:666–669.
61. Gonsoulin W, Borge D, Moise KJ. Rupture of unscarred uterus in primigravid woman in association with cocaine
abuse. Am J Obstet Gynecol. 1990;163:526–527.
62. Fares I, McCulloch KM, Raju T. Intrauterine cocaine
exposure and the risk for sudden infant death syndrome: a meta-analysis. J Perinatol
63. Chasnoff IJ, Lewis DE, Squires L. Cocaine
intoxication in a breast-fed infant. Pediatrics. 1987;80:836–838.
64. American Academy of Pediatrics Committee on Durgs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–778.
65. American College of Obstetricians and Gynecologists. Committee Opinion No. 711: opioid use and opioid use disorder in pregnancy
. Obstet Gynecol. 2017;130:e81–e94.
66. Singer L, Arendt R, Farkas K, et al. Relationship of prenatal cocaine
exposure and maternal postpartum psychological distress to child developmental outcome. Dev Psychopathol. 1997;9:473–489.
67. Accornero VH, Anthony JC, Morrow CE, et al. Estimated effect of prenatal cocaine
exposure on examiner-rated behavior at age 7 years. Neurotoxicol Teratol. 2011;33:370–378.
68. Richardson GA, Goldschmidt L, Larkby C, et al. Effects of prenatal cocaine
exposure on adolescent development. Neurotoxicol Teratol. 2015;49:41–48.
69. Bridgett DJ, Mayes LC. Development of inhibitory control among prenatally cocaine
exposed and non-cocaine
exposed youths from late childhood to early adolescence: the effects of gender and risk and subsequent aggressive behavior. Neurotoxicol Teratol. 2011;33:47–60.
70. Carmody DP, Bennett DS, Lewis M. The effects of prenatal cocaine
exposure and gender on inhibitory control and attention. Neurotoxicol Teratol. 2011;33:61–68.
71. Frank DA, Augustyn M, Knight WG, et al. Growth, development, and behavior in early childhood following prenatal cocaine
exposure: a systematic review. JAMA. 2001;285:1613–1625.
72. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine
. Addiction. 2009;104:1085–1099.
73. Elkashef A, Vocci F, Hanson G, et al. Pharmacotherapy of methamphetamine
addiction: an update. Subst Abus. 2008;29:31–49.
74. Hart CL, Gunderson EW, Perez A, et al. Acute physiological and behavioral effects of intranasal methamphetamine
in humans. Neuropsychopharmacology. 2008;33:1847–1855.
75. Miller CL, Kerr T, Fischer B, et al. Methamphetamine
injection independently predicts hepatitis C infection among street-involved youth in a Canadian setting. J Adolesc Health. 2009;44:302–304.
76. Anderson R, Flynn NKlee H. The methamphetamine
-HIV connection in Northern California. Amphetamine Misuse: International Perspectives on Current Trends. Amsterdam: Harwood Academic Publishers; 1997:181–196.
77. Warner M, Chen LH, Makuc DM, et al. Drug poisoning deaths in the United States, 1980-2008. NCHS Data Brief. 2011;81:1–8.
78. Al-Tayyib A, Koester S, Langegger S, et al. Heroin and methamphetamine
injection: an emerging drug use pattern. Subst Use Misuse. 2017;52:1051–1058.
79. Kuo CJ, Liao YT, Chen WJ, et al. Causes of death of patients with methamphetamine
dependence: a record‐linkage study. Drug Alcohol Rev. 2011;30:621–628.
80. Zapata LB, Hillis SD, Marchbanks PA, et al. Methamphetamine
use is independently associated with recent risky sexual behaviors and adolescent pregnancy
. J Sch Health. 2008;78:641–648.
81. Shah R, Diaz SD, Arria A, et al. Prenatal methamphetamine
exposure and short-term maternal and infant medical outcomes. Am J Perinatol. 2012;29:391–400.
82. Derauf C, LaGasse LL, Smith LM, et al. Demographic and psychosocial characteristics of mothers using methamphetamine
: preliminary results of the infant development, environment, and lifestyle study (IDEAL). Am J Drug Alcohol Abuse. 2007;33:281–289.
83. Gorman MC, Orme KS, Nguyen NT, et al. Outcomes in pregnancies complicated by methamphetamine
use. Am J Obstet Gynecol. 2014;211:429. e1–e7.
84. Nguyen D, Smith LM, LaGasse LL, et al. Intrauterine growth of infants exposed to prenatal methamphetamine
: results from the infant development, environment, and lifestyle study. J Pediatr. 2010;157:337–339.
85. Barlow A, Mullany BC, Neault N, et al. Examining correlates of methamphetamine
and other drug use in pregnant American Indian adolescents. Am Indian Alaska Native Ment Health Res. 2010;17:1–24.
86. McElhatton P. Fetal effects of substances of abuse. J Toxicol Clin Toxicol. 2000;38:194–195.
87. Eriksson M, Larsson G, Zetterström R. Amphetamine addiction and pregnancy
. Acta Obstet Gynecol Scand. 1981;60:253–259.
88. Good MM, Solt I, Acuna JG, et al. Methamphetamine
use during pregnancy
: maternal and neonatal implications. Obstet Gynecol. 2010;116:330–334.
89. Kalaitzopoulos D-R, Chatzistergiou K, Amylidi A-L, et al. Effect of methamphetamine
hydrochloride on pregnancy
outcome: a systematic review and meta-analysis. J Addict Med. 2018;12:220–226.
90. Gilbert EF, Khoury GH. Dextroamphetamine and congenital cardiac malformations. J Pediatr. 1970;76:638.
91. Nora J, Vargo T, Nora A, et al. Dexamphetamine: a possible environmental trigger in cardiovascular malformations. Lancet. 1970;295:1290–1291.
92. Draper ES, Rankin J, Tonks AM, et al. Recreational drug use: a major risk factor for gastroschisis? Am J Epidemiol. 2007;167:485–491.
93. Bays J. Fetal vascular disruption with prenatal exposure to cocaine
. Pediatrics. 1991;87:416–417.
94. Levin JN. Amphetamine ingestion with biliary atresia. J Pediatr. 1971;79:130–131.
95. Matera R, Zabala H, Jimenez A. Bifid exencephalia. Teratogen action of amphetamine. Int Surg. 1968;50:79–85.
96. Milkovich L, van den Berg BJ. Effects of antenatal exposure to anorectic drugs. Am J Obstet Gynecol. 1977;129:637–642.
97. Little BB, Snell LM. Methamphetamine
abuse during pregnancy
: outcome and fetal effects. Obstet Gynecol. 1988;72:541–544.
98. Oro AS, Dixon SD. Perinatal cocaine
exposure: maternal and neonatal correlates. J Pediatr. 1987;111:571–578.
99. Smith L, Yonekura ML, Wallace T, et al. Effects of prenatal methamphetamine
exposure on fetal growth and drug withdrawal symptoms in infants born at term. J Dev Behav Pediatr. 2003;24:17–23.
100. Jablonski SA, Williams MT, Vorhees CV. Mechanisms involved in the neurotoxic and cognitive effects of developmental methamphetamine
exposure. Birth Defects Res C Embryo Today. 2016;108:131–141.
101. Davidson C, Gow AJ, Lee TH, et al. Methamphetamine
neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev. 2001;36:1–22.
102. Won L, Bubula N, McCoy H, et al. Methamphetamine
concentrations in fetal and maternal brain following prenatal exposure. Neurotoxicol Teratol. 2001;23:349–354.
103. Won L, Bubula N, Heller A. Fetal exposure to methamphetamine
in utero stimulates development of serotonergic neurons in three‐dimensional reaggregate tissue culture. Synapse. 2002;43:139–144.
104. Heller A, Bubula N, Lew R, et al. Gender-dependent enhanced adult neurotoxic response to methamphetamine
following fetal exposure to the drug. J Pharmacol Exp Ther. 2001;298:769–779.
105. Chang L, Smith LM, LoPresti C, et al. Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine
exposure. Psychiatry Res. 2004;132:95–106.
106. Smith L, Chang L, Yonekura M, et al. Brain proton magnetic resonance spectroscopy in children exposed to methamphetamine
in utero. Neurology. 2001;57:255–260.
107. Arria AM, Derauf C, LaGasse LL, et al. Methamphetamine
and other substance use during pregnancy
: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study. Matern Child Health J. 2006;10:293–302.
108. LaGasse LL, Wouldes T, Newman E, et al. Prenatal methamphetamine
exposure and neonatal neurobehavioral outcome in the USA and New Zealand. Neurotoxicol Teratol. 2011;33:166–175.
109. Smith LM, LaGasse LL, Derauf C, et al. Prenatal methamphetamine
use and neonatal neurobehavioral outcome. Neurotoxicol Teratol. 2008;30:20–28.
110. Kiblawi ZN, Smith LM, Diaz SD, et al. Prenatal methamphetamine
exposure and neonatal and infant neurobehavioral outcome: results from the IDEAL study. Subst Abus. 2014;35:68–73.
111. Smith LM, Paz MS, LaGasse LL, et al. Maternal depression and prenatal exposure to methamphetamine
: neurodevelopmental findings from the infant development, environment, and lifestyle (ideal) study. Depress Anxiety. 2012;29:515–522.
112. Derauf C, LaGasse L, Smith L, et al. Infant temperament and high risk environment relate to behavior problems and language in toddlers. J Dev Behav Pediatr. 2011;32:125–135.
113. LaGasse LL, Derauf C, Smith LM, et al. Prenatal methamphetamine
exposure and childhood behavior problems at 3 and 5 years of age. Pediatrics. 2012;129:681–688.
114. Derauf C, LaGasse LL, Smith LM, et al. Prenatal methamphetamine
exposure and inhibitory control among young school-age children. J Pediatr. 2012;161:452–459.
115. Diaz SD, Smith LM, LaGasse LL, et al. Effects of prenatal methamphetamine
exposure on behavioral and cognitive findings at 7.5 years of age. J Pediatr. 2014;164:1333–1338.
116. Chang L, Cloak C, Jiang C, et al. Altered neurometabolites and motor integration in children exposed to methamphetamine
in utero. Neuroimage. 2009;48:391–397.
117. Roussotte FF, Bramen JE, Nunez SC, et al. Abnormal brain activation during working memory in children with prenatal exposure to drugs of abuse: the effects of methamphetamine
, alcohol, and polydrug exposure. Neuroimage. 2011;54:3067–3075.
118. Roussotte FF, Rudie JD, Smith L, et al. Frontostriatal connectivity in children during working memory and the effects of prenatal methamphetamine
, alcohol, and polydrug exposure. Dev Neurosci. 2012;34:43–57.
119. Colby JB, Smith L, O’Connor MJ, et al. White matter microstructural alterations in children with prenatal methamphetamine
/polydrug exposure. Psychiatry Res. 2012;204:140–148.
120. Roos A, Jones G, Howells FM, et al. Structural brain changes in prenatal methamphetamine
-exposed children. Metab Brain Dis. 2014;29:341–349.
121. Roos A, Kwiatkowski MA, Fouche J-P, et al. White matter integrity and cognitive performance in children with prenatal methamphetamine
exposure. Behav Brain Res. 2015;279:62–67.
122. Bartu A, Dusci LJ, Ilett KF. Transfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine. Br J Clin Pharmacol. 2009;67:455–459.
123. McCabe SE, Knight JR, Teter CJ, et al. Non‐medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction. 2005;100:96–106.
124. Teter CJ, McCabe SE, LaGrange K, et al. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy. 2006;26:1501–1510.
125. Baker AS, Freeman MP. Management of attention deficit hyperactivity disorder during pregnancy
. Obste Gynecol Clin. 2018;45:495–509.
126. Huybrechts KF, Bröms G, Christensen LB, et al. Association between methylphenidate and amphetamine use in pregnancy
and risk of congenital malformations: a cohort study from the international pregnancy
safety study consortium. JAMA Psychiatry. 2018;75:167–175.
127. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy
. Pharmaceuticals. 2013;6:1221–1286.
128. Pottegård A, Hallas J, Andersen JT, et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry. 2014;75:88–93.
129. Cohen JM, Hernández-Díaz S, Bateman BT, et al. Placental complications associated with psychostimulant use in pregnancy
. Obstet Gynecol. 2017;130:1192–1201.
130. Nörby U, Winbladh B, Källén K. Perinatal outcomes after treatment with ADHD medication during pregnancy
. Pediatrics. 2017;140:e20170747.
131. Poulton AS, Armstrong B, Nanan RK. Perinatal outcomes of women diagnosed with attention-deficit/hyperactivity disorder: an Australian population-based cohort study. CNS Drugs. 2018;32:377–386.
132. Steiner E, Villen T, Hallberg M, et al. Amphetamine secretion in breast milk. Eur J Clin Pharmacol. 1984;27:123–124.
133. Ayd FJ Jr. Excretion of psychotropic drugs in human breast milk. Psychopharm Rev. 1973;8:33–40.
134. Landry MJ. MDMA: a review of epidemiological data. J Psychoactive Drugs. 2002;34:163–169.
135. Singer LT, Moore DG, Fulton S, et al. Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy
) and other recreational drugs during pregnancy
. Neurotoxicol Teratol. 2012;34:303–310.
136. van Tonningen MR, Garbis H, Reuvers M. Ecstasy
exposure during pregnancy
. Teratology. 1998;58:33A.
137. Colado M, O’shea E, Granados R, et al. A study of the neurotoxic effect of MDMA (“ecstasy
”) on 5‐HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy
. Br J Pharmacol. 1997;121:827–833.
138. Singer LT, Moore DG, Min MO, et al. One-year outcomes of prenatal exposure to MDMA and other recreational drugs. Pediatrics. 2012;130:407–413.
139. Singer LT, Moore DG, Min MO, et al. Developmental outcomes of 3, 4‐methylenedioxymethamphetamine (ecstasy
)‐exposed infants in the UK. Human Psychopharmacol Clin. 2015;30:290–294.
140. Singer LT, Moore DG, Min MO, et al. Motor delays in MDMA (ecstasy
) exposed infants persist to 2 years. Neurotoxicol Teratol. 2016;54:22–28.
141. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000;343:1833–1838.
142. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with Ma Huang, an herbal source of ephedrine. Paper presented at Mayo Clinic Proceedings, 2002.
143. Maglione M, Miotto K, Iguchi M, et al. Psychiatric effects of ephedra use: an analysis of Food and Drug Administration reports of adverse events. Am J Psychiatry. 2005;162:189–191.
144. Kennedy J. Herb and supplement use in the US adult population. Clin Ther. 2005;27:1847–1858.
145. Broussard CS, Louik C, Honein MA, et al. NBDP Study. Herbal use before and during pregnancy
. Am J Obstet Gynecol. 2010;202:443.e1–e6.
146. Bitsko RH, Reefhuis J, Louik C, et al. Periconceptional use of weight loss products including ephedra and the association with birth defects. Birth Defects Res A Clin Mol Teratol. 2008;82:553–562.
148. Miller BL, Stogner JM, Miller JM, et al. The arrest and synthetic novel psychoactive drug relationship: observations from a young adult population. J Drug Issues. 2017;47:91–103.
149. John ME, Thomas-Rozea C, Hahn D. Bath salts
abuse leading to new-onset psychosis and potential for violence. Clin Schizophr Relat Psychoses. 2017;11:120–124.
150. Miotto K, Striebel J, Cho AK, et al. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend. 2013;132:1–12.
151. Baumann MH, Partilla JS, Lehner KR, et al. Powerful cocaine
-like actions of 3, 4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts
’ products. Neuropsychopharmacology. 2013;38:552–562.
152. Palamar JJ. “Bath salt” use among a nationally representative sample of high school seniors in the United States. Am J Addict. 2015;24:488–491.
153. Johnson PS, Johnson MW. Investigation of “bath salts
” use patterns within an online sample of users in the United States. J Psychoactive Drugs. 2014;46:369–378.
154. Khawaja M, Al-Nsour M, Saad G. Khat (Catha edulis) chewing during pregnancy
in Yemen: findings from a national population survey. Matern Child Health J. 2008;12:308–312.
155. Hassan N, Gunaid A, Murray Lyon I. Khat (Catha edulis): health aspects of khat chewing. East Mediterr Health J. 2007;13:706–718.
156. Mwenda JM, Arimi MM, Kyama MC, et al. Effects of khat (Catha edulis) consumption on reproductive functions: a review. East Afr Med J. 2003;80:318–323.
157. Nakajima M, Jebena MG, Taha M, et al. Correlates of khat use during pregnancy
: a cross-sectional study. Addict Behav. 2017;73:178–184.
158. Kristiansson B, Abdul Ghani N, Eriksson M, et al. Use of khat in lactating women: a pilot study on breast-milk secretion. J Ethnopharmacol. 1987;21:85–90.
159. Ibrahim Ali Omer M, Mansoub MA, Omer R, et al. The effect of qat chewing and other factors on breast-feeding and child survival in a Yemeni society. Sudan J Paediatr. 2011;11:14–20.
160. de Lima MS, de Oliveira Soares BG, Reisser AA, et al. Pharmacological treatment of cocaine
dependence: a systematic review. Addiction. 2002;97:931–949.
161. Dutra L, Stathopoulou G, Basden SL, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165:179–187.
162. Prendergast M, Podus D, Finney J, et al. Contingency management for treatment of substance use disorders: a meta‐analysis. Addiction. 2006;101:1546–1560.
163. Wright TE, Terplan M, Ondersma SJ, et al. The role of screening, brief intervention, and referral to treatment in the perinatal period. Am J Obstet Gynecol. 2016;215:539–547.
164. Madsen AM, Stark LM, Has P, et al. Opioid knowledge and prescribing practices among obstetrician-gynecologists. Obstet Gynecol. 2018;131:150–157.
165. Schiff DM, Nielsen T, Terplan M, et al. Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts. Obstet Gynecol. 2018;132:466–474.
166. Platner M, Loucks TL, Lindsay MK, et al. Pregnancy
-associated deaths in rural, nonrural, and metropolitan areas of Georgia. Obstet Gynecol. 2016;128:113–120.